BioXcel Therapeutics (BTAI) Total Debt (2018 - 2026)

BioXcel Therapeutics' Total Debt history runs 9 years deep, the most recent figure standing at $100.3 million for Q1 2026.

• In Q1 2026, Total Debt fell 4.96% year-over-year to $100.3 million; the TTM figure through Mar 2026 stood at $100.3 million (down 4.96% YoY), while the FY2025 annual figure was $109.6 million, up 6.91% from the prior year.
• Total Debt was $100.3 million for Q1 2026 at BioXcel Therapeutics, down from $109.6 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $109.6 million in Q4 2025 to a low of $56000.0 in Q1 2022.
• Historically, Total Debt has averaged $93.2 million across 5 years, with a median of $100.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Total Debt surged 170332.14% in 2023, then declined 4.96% in 2026.
• A 5-year view of Total Debt shows it stood at $93.5 million in 2022, then grew by 7.62% to $100.6 million in 2023, then increased by 1.9% to $102.5 million in 2024, then rose by 6.91% to $109.6 million in 2025, then slipped by 8.49% to $100.3 million in 2026.
• The last three Total Debt figures came in at $100.3 million (Q1 2026), $109.6 million (Q4 2025), and $109.1 million (Q3 2025), per Business Quant data.